Examination of gastrointestinal-mediated hypoglycemic effects of imeglimin

Kazuhiko Sakaguchi0 个研究点目标入组 10 人开始时间: 2023年3月15日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. Patients with type 2 diabetes medically considered to require glycemic control with additional medication
•2. Patients not taking imeglimin for at least 1 month prior to obtaining consent
•3. [Imeglimin alone group] patients not taking metformin for at least 1 month prior to obtaining consent, and [Imeglimin and metformin combination group] patients taking metformin (more than 1000 mg per day) for at least 1 month prior to obtaining consent
•4. Patients without the lower gastrointestinal tract disease
•5. Patients who are over 20 years old and within 80 years old at the time of obtaining consent
•6. Patients who have given their voluntary written consent to participate in this clinical study

•1. Patients with the following contraindications to butylscopolamine bromide
•2. Patients with dementia or psychiatric disorders
•3. Patients with intestinal perforation or obstruction
•4. Patients with metals in the body that are not amenable to PET/MRE testing
•5. Pregnant or breast feeding patients
•6. Other patients deemed inappropriate by the investigators in charge of this clinical study

发起方

Kazuhiko Sakaguchi